Mostrar el registro sencillo del ítem

dc.contributor.authorRecio-Barbero, María
dc.contributor.authorSegarra, Rafael
dc.contributor.authorZabala, Arantzazu
dc.contributor.authorGonzález-Fraile, Eduardo (1)
dc.contributor.authorGonzález-Pinto, Ana
dc.contributor.authorBallesteros, Javier
dc.date2021
dc.date.accessioned2021-07-23T12:31:31Z
dc.date.available2021-07-23T12:31:31Z
dc.identifier.issn1664-0640
dc.identifier.urihttps://reunir.unir.net/handle/123456789/11656
dc.description.abstractBackground: Schizophrenia is a severe and enduring disease and is one of the leading causes of disability worldwide. Cognitive impairment is a core clinical symptom that plays a crucial role in functional outcomes and prognosis, thus making it a relevant treatment target. The aim of this study was to assess the efficacy of alpha-7 nicotinic acetylcholine receptor agonists (α7 nAChR) as adjunctive treatment to enhance cognition and ameliorate negative symptoms in patients with schizophrenia. Methods: A search strategy was developed for MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials up to May 2019. We included randomized controlled trials (RCTs) that compared antipsychotic treatment plus α7 nAChR agonists with antipsychotic treatment plus placebo and determined their effects on the main cognitive domains proposed by the MATRICS initiative and on negative symptoms. Two authors independently reviewed study eligibility and data extraction and assessed the risk of bias of the studies included. According to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, we used a random-effects model and assessed the quality of the evidence. Results: Thirteen studies were included in the quantitative analysis. No differences were found in any of the cognitive domains assessed in four RCTs (n = 414). In contrast, nine RCTs (n = 978) presented a small effect in support of α7 nAChR agonists for negative symptoms [standardized mean difference −0.28, 95% CI (−0.56 to −0.00); P = 0.05], even though the confidence to support this evidence is low according to the GRADE system. Conclusions: Current evidence is too weak to consider α7 nAChR agonists as an effective add-on treatment to antipsychotics to enhance cognition and negative symptoms.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers in Psychiatryes_ES
dc.relation.ispartofseries;vol. 12
dc.relation.urihttps://www.frontiersin.org/articles/10.3389/fpsyt.2021.631589/fulles_ES
dc.rightsopenAccesses_ES
dc.subjectalpha-7 agonistses_ES
dc.subjectcognitive dysfunctiones_ES
dc.subjectnegative symptomses_ES
dc.subjectnicotinic agonistses_ES
dc.subjectschizophreniaes_ES
dc.subjectScopuses_ES
dc.subjectWOS(2)es_ES
dc.titleCognitive Enhancers in Schizophrenia: A Systematic Review and Meta-Analysis of Alpha-7 Nicotinic Acetylcholine Receptor Agonists for Cognitive Deficits and Negative Symptomses_ES
dc.typeArticulo Revista Indexadaes_ES
reunir.tag~ARIes_ES
dc.identifier.doihttps://doi.org/10.3389/fpsyt.2021.631589


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem